Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017;2(5):249-260.
doi: 10.1080/23808993.2017.1372687. Epub 2017 Sep 5.

Tissue-based biomarkers in prostate cancer

Timothy N Clinton  1 , Aditya Bagrodia  1 , Yair Lotan  1 , Vitaly Margulis  1 , Ganesh V Raj  1 , Solomon L Woldu  1
Affiliations

Tissue-based biomarkers in prostate cancer

Timothy N Clinton et al. Expert Rev Precis Med Drug Dev. 2017.

Abstract

Introduction: Prostate cancer is a heterogeneous disease. Existing risk stratification tools based on standard clinlicopathologic variables (prostate specific antigen [PSA], Gleason score, and tumor stage) provide a modest degree of predictive ability. Advances in high-throughput sequencing has led to the development of several novel tissue-based biomarkers that can improve prognostication in prostate cancer management.

Areas covered: The authors review commercially-available, tissue-based biomarker assays that improve upon existing risk-stratification tools in several areas of prostate cancer management, including the appropriateness of active surveillance and aiding in decision making regarding the use of adjuvant therapy. Additionally, some of the obstacles to the widespread adoption of these biomarkers and discuss several investigational sources of new biomarkers are discussed.

Expert commentary: Work is ongoing to answer pertinent clinical questions in prostate cancer management including which patients should undergo biopsy, active surveillance, receive adjuvant therapy, and what systemic therapy is best in the first-line. Incorporation into novel biomarkers may allow for the incorporation of a 'personalized' approach to management. Further validation will be required and questions of cost must be considered before wide scale adoption of these biomarkers. Tumor heterogeneity may impose a ceiling on the prognostic ability of biomarkers using currently available techniques.

Keywords: active surveillance; adjuvant therapy; biomarker; genomics; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interest: Y Lotan discloses research with MDxHealth, Inc. and Genomic Health. V Margulis is a consultant for MDxHealth and Genomic Health. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Figures

Figure 1
Figure 1. Utility of Tissue-Based Biomarkers in Prostate Cancer Management
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. - PubMed
    1. Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. - PubMed
    1. Cooperberg MR, Chan JM. Epidemiology of prostate cancer. World J Urol. 2017 - PubMed
    1. Shao YH, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009;101(18):1280–3. - PMC - PubMed
    1. Welch HG, Gorski DH, Albertsen PC. Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics. N Engl J Med. 2015;373(18):1685–7. - PubMed